Instruction for use: Suprefakt

ATX Code L02AE01 Buserelin

Pharmacological group

Antineoplastic hormonal agents and hormone antagonists

Nosological classification (ICD-10)

C61 Malignant neoplasm of prostate

Adenocarcinoma of the prostate, Hormone-dependent prostate cancer, Hormone-Resistant Prostate Cancer, Malignant tumor of prostate, Malignant neoplasm of prostate, Carcinoma of the prostate, Locally-distributed non-metastatic prostate cancer, Locally advanced prostate cancer, Locally spread prostate cancer, Metastatic prostatic carcinoma, Metastatic prostate cancer, Metastatic hormone-resistant prostate cancer, Non-metastatic prostate cancer, Incompatible prostate cancer, Prostate Cancer, Prostate cancer, Common prostate cancer, Testosterone-Depot Prostate Cancer

Composition

1 ml of solution for injection contains buserelin 3 mg; In bottles of 5.5 ml, in the package 1 pc.

1 dose of aerosol for intranasal use - 0.1 mg; In the bottle 200 doses; In the package 1 pc.

pharmachologic effect

Pharmacological action - antiandrogenic.

Suppresses the secretion of luteinizing hormone and the synthesis of testosterone.

Pharmacokinetics

It is well resorbed through the nasal mucosa, creating high concentrations in the blood plasma.

Clinical Pharmacology

The concentration of testosterone with continuous use of the drug within 14-21 days decreases to a level characteristic of the state of orchiectomy.

Indication

Prostate cancer (testosterone-dependent).

Contraindications

Hypersensitivity.

Side effects

Nausea, vomiting, abdominal pain, rarely - gynecomastia, impotence, decreased libido, thrombosis; In patients with pain in the bones, their strengthening is possible.

Dosing and Administration

The first 7 days - p / c of 500 mcg 3 times a day (every 8 h). On the 8th day they switch to intranasal administration: 2 doses before and after breakfast, lunch and dinner. With confirmed hormone-dependent prostate tumors, the course can last a lifetime.

Precautionary measures

It is not recommended to appoint patients with a pituitary tumor. It should be ensured that the patient does not arbitrarily stop taking the drug and did not change the dose. With prolonged therapy, the drug should be used in the form of an aerosol.

storage Conditions

Keep out of the reach of children.